同花顺美股讯 1月21日TD Cowen评级报告首次覆盖forte biosciences,首次评级为买入。Forte Biosciences于11月14日发布2024年三季报,公司截至2024年9月30日,净利润-2832.30万美元,基本每股收益-15.35美元。Forte Biosciences, Inc.是一家临床阶段的皮肤病学公司,致力于开发用于治疗炎症性皮肤病的活体生物疗法FB-401...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.